PPARG and lung carcinoma: Our group has shown that PPARγ agonists including ciglitazone, troglitazone,and GW1929 induce the expression of death receptor 5 (DR5) including increasingthe cell surface distribution of DR5, reducing the levels of c-FLIP, andenhancing TRAIL-induced apoptosis in human lung cancer cells [34].